Combined Holdings of Vertex Pharmaceuticals (VRTX) - Updated Daily
Join Premium Plan
Key Statistics
EarningsSee Full Calendar
| Date | May 05, 2022 | Revenue | Expected0 Actual$2.10b | EPS | Expected$3.49 Actual$3.52 |
|---|
Statistics
Clinical Trials (69)
Institutional Ownership Trends
News That Matters
| 🕵🏼Found In | 🏷Last Price |
|---|---|
| ARKG | $258.59 |
| ⚖️Weighting | 🧢Market Cap |
| 0.63% | $66.14b |
| 🏋️♀️Weight Rank Across All Funds | 🧮Price to Sales |
| 34 | 8.32 |
| 💳ARK Estimated Cost Average | 🌏Country |
$225.49 - ARKG | 🇺🇸United States |
| 🎫ARK Ownership Percent | |
| 0.15% | |
| Description | |
|---|---|
| Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) - a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus. | |
| Website | |
| www.vrtx.com |
Research Notes and Commentary for VRTX
March 10, 2021
March 10, 2021: ARK Trades and Storylines
Trading Floor